Previous studies have suggested that GDNF/RET tyrosine kinase activates mitogen-activated protein kinase (MAPK) signaling components leading to endocrine resistant ERα+ breast cancer [1, 9–11] by promoting cell survival and proliferation that persists in the presence of endocrine therapies. Here, ESR1 is linked to breast carcinoma.